Vancomycin plus Rifampin — Competitive Intelligence Brief

Vancomycin plus Rifampin (Vancomycin plus Rifampin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination. Area: Infectious Disease.

marketed Antibiotic combination Bacterial cell wall (vancomycin) and bacterial RNA polymerase (rifampin) Infectious Disease Small molecule

Target snapshot

Vancomycin plus Rifampin (Vancomycin plus Rifampin) — Michael E. DeBakey VA Medical Center. Vancomycin and rifampin work synergistically to inhibit bacterial cell wall and protein synthesis, providing broad-spectrum bactericidal activity against resistant gram-positive organisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vancomycin plus Rifampin TARGET	Vancomycin plus Rifampin	Michael E. DeBakey VA Medical Center	marketed	Antibiotic combination	Bacterial cell wall (vancomycin) and bacterial RNA polymerase (rifampin)
ceftriaxone and azithromycin	ceftriaxone and azithromycin	Sheba Medical Center	marketed	Beta-lactam antibiotic and macrolide antibiotic combination	Bacterial cell wall (ceftriaxone) and bacterial 50S ribosome (azithromycin)
Early Dual IV Antibiotic Therapy - MSSA	Early Dual IV Antibiotic Therapy - MSSA	West Virginia University	marketed	Antibiotic combination therapy
Polysporin Triple	Polysporin Triple	University Health Network, Toronto	marketed	Topical antibiotic combination	Bacterial cell wall (bacitracin), bacterial ribosome (neomycin), bacterial cell membrane (polymyxin B)
PPI, amoxicillin, metronidazole and clarithromycin	PPI, amoxicillin, metronidazole and clarithromycin	Infante, Javier Molina, M.D.	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; metronidazole and clarithromycin target bacterial protein synthesis
prednison, azithromycin	prednison, azithromycin	Tel-Aviv Sourasky Medical Center	marketed	Corticosteroid + Macrolide antibiotic combination	Glucocorticoid receptor (prednisone); bacterial 50S ribosome (azithromycin)
Benzoyl peroxide with clindamycin	Benzoyl peroxide with clindamycin	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Bacterial ribosomes (clindamycin); reactive oxygen species generation (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination class)

1. Michael E. DeBakey VA Medical Center · 2 drugs in this class
2. University of South Florida · 2 drugs in this class
3. Halmstad County Hospital · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Hospital de Clinicas de Porto Alegre · 1 drug in this class
6. McMaster University · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. The Cleveland Clinic · 1 drug in this class
10. The Forsyth Institute · 1 drug in this class